Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Critics say Canada’s new immigration and border law puts LGBTQ+ people in danger

June 13, 2026

Microsoft hasn’t ruled out spinning off Xbox

June 13, 2026

Bose’s latest QuietComfort Ultra are $70 off, marking a new low price 

June 13, 2026

My first 24 hours with Siri AI on the Mac

June 13, 2026

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

June 13, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Saladax Biomedical Inc. Welcomes Dr. Sepideh Fanaei as Country Manager for DACH Region, Supporting EU Expansion and Revenue Growth
Press Release

Saladax Biomedical Inc. Welcomes Dr. Sepideh Fanaei as Country Manager for DACH Region, Supporting EU Expansion and Revenue Growth

By News RoomNovember 21, 20242 Mins Read
Saladax Biomedical Inc. Welcomes Dr. Sepideh Fanaei as Country Manager for DACH Region, Supporting EU Expansion and Revenue Growth
Share
Facebook Twitter LinkedIn Pinterest Email

Bethlehem, PA, Nov. 21, 2024 (GLOBE NEWSWIRE) — Saladax Biomedical, Inc. is thrilled to announce the appointment of Dr. Sepideh Fanaei as Country Manager for the DACH region, which encompasses Germany, Austria, and Switzerland. This new role signifies a critical step in Saladax’s European expansion strategy, which aims to advance the company’s growth in the EU healthcare market.

Dr. Fanaei joins Saladax with over 20 years of experience in Germany’s healthcare and biotechnology sectors, where her expertise spans market access, commercial strategy, and business growth. Her impactful leadership in oncology, neurology, and women’s health has elevated market presence and driven successful expansion, establishing her as a highly regarded figure in the industry.

“As we introduce Saladax’s rapid Antipsychotic Therapeutic Drug Monitoring (TDM) assays to European markets, Dr. Fanaei’s leadership will be instrumental in driving growth and increasing revenue across the DACH region,” said Maria Foster, Chief Commercial Officer at Saladax.

The Saladax TDM assays and the MyCare Insite Point of Care device are designed to fill a crucial clinical gap for patients with serious mental illness (SMI), offering healthcare providers rapid, cost-effective, and precise blood-level monitoring of antipsychotic drugs.

Expressing her enthusiasm, Dr. Fanaei stated, “For the first time, healthcare providers will have access to TDM data precisely when important clinical decisions are made, enabling more effective and individualized patient care. I am honored to join an organization that places patient health and innovation at the core of its mission.”

ABOUT SALADAX BIOMEDICAL, INC. 

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax’s proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com 


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

BMI EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Badger Meter (BMI) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Hyderabad Sees Surge in Dining Table Rentals in 2026 as Salaried IT Professionals Reject ₹45,000 EMI Lock-Ins for ₹1,400/Month Plans From Rentomojo

PHR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

RBLX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Notifies Roblox (RBLX) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

Don’t Pay Full Price for Power: WattCycle’s Prime Day Event Drops Up to 70% Off LiFePO4 Batteries Starting June 15

AVAV EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds AeroVironment (AVAV) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Editors Picks

Microsoft hasn’t ruled out spinning off Xbox

June 13, 2026

Bose’s latest QuietComfort Ultra are $70 off, marking a new low price 

June 13, 2026

My first 24 hours with Siri AI on the Mac

June 13, 2026

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zscaler

June 13, 2026

Latest News

Never Post’s Mike Rugnetta on the creative process and the value of reliable power

June 13, 2026

BTGO EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds BitGo Holdings (BTGO) Investors of Securities Class Action Lawsuit Deadline on August 7, 2026

June 13, 2026

FemiCore (Official Website & Authenticity Notice 2026) – Counterfeit Risks and What Consumers Should Know

June 13, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version